Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

220.54
-17.9700-7.53%
Post-market: 220.37-0.1700-0.08%19:56 EDT
Volume:700.30K
Turnover:154.81M
Market Cap:23.72B
PE:-36.01
High:235.03
Open:220.15
Low:214.12
Close:238.51
Loading ...

Company Profile

Company Name:
BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
11000
Office Location:
94 Solaris Avenue,Camana Bay,Grand Cayman,Cayman Islands
Zip Code:
KY1-1108
Fax:
- -
Introduction:
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Directors

Name
Position
John V. Oyler
Chief Executive Officer and Chairman
Ranjeev Krishana
Lead Director
Alessandro Riva
Director
Anthony C. Hooper
Director
Corazon D. Sanders
Director
Donald W. Glazer
Director
Margaret Dugan
Director
Michael Goller
Director
Olivier Brandicourt
Director
Qingqing Yi
Director
Shalini Sharp
Director
Xiaodong Wang
Director

Shareholders

Name
Position
John V. Oyler
Chief Executive Officer and Chairman
Xiaobin Wu
President, Chief Operating Officer and General Manager of China
Aaron Rosenberg
Chief Financial Officer
Chan Lee
Senior Vice President, General Counsel
Lai Wang
Global Head of R& D